Hudson Bay Capital Management is a hedge fund in New York that that provides management services. Founded 2005 in New York, United States, the company invests in Series B rounds. Hudson Bay Capital Management has invested in Alphamab Oncology on May 28, 2019. This investment in the Series B round of Alphamab Oncology was valued at $60M. Alphamab Oncology is a clinical-stage biopharmaceutical company. Hudson Bay Capital Management later exited this company.
The company is a multi-billion dollar asset management firm operating in New York and London. Hudson Bay Capital is the successor to Gerber Asset Management LLC, a proprietary investment firm established by Hudson Bay’s founder Sander Gerber.